A female researcher looks through a microscope
Gastroenterology & Hepatology: Clinical & Research Programs

The faculty members at the U-M Medical School Department of Internal Medicine Division of Gastroenterology & Hepatology are involved in a wide range of basic, translational and clinical research programs that span all of the gastroenterology and hepatology sub-specialty areas.
Dedicated to Expertise

Comprehensive Pancreas Program: A program that aims to provide the best possible clinical care for patients with pancreatic disorders through patient-centered clinical care, education, innovative research and multidisciplinary collaboration.

Esophageal Disorders Program: This program integrates consultative services and endoscopic therapy, along with cutting-edge patient-oriented and translational research, to improve treatment for patients with esophageal disorders.

Functional Bowel Disorders Program: This program provides patient education and contributes to clinical research related to FBD. Our team of caring experts are equipped to help patients develop a plan for diagnosing and treating different types of bowel disorders.

Hepatology Program: A program that has been advancing research, educating health care professionals and providing compassionate care to patients affected by all forms of liver disease for over 50 years. It includes over 20 faculty members and advanced practice providers with expertise in a wide variety of liver diseases.

Inflammatory Bowel Disease Program: An internationally recognized group of clinicians, surgeons, researchers and educators dedicated to the management of the inflammatory bowel diseases. Our specialists work to provide complete care for the complex issues associated with Crohn's disease and ulcerative colitis.

Interventional Endoscopy Program: A program that strives to provide state-of-the-art clinical care, education and research. Our faculty have contributed to the development of national guidelines on standard endoscopic practices, are part of journal editorial boards, and are often invited as speakers at national conferences.

Michigan Bowel Control Program: A multidisciplinary program that specializes in the diagnosis and treatment of defecation disorders and other disorders of the posterior pelvic floor. This expert team strives to increase understanding of the physiology of conditions, implement new therapies and technologies and improve treatment results for patients through ongoing clinical trials and basic science research.
Featured News & Stories See all news 27th Annual Liver Disease Wrap-Up
Department News
27th Annual Liver Disease Wrap-Up
Join us for the 27th Annual Liver Disease Wrap-Up conference taking place on Saturday, December 7, 2024
 machine beige black
Health Lab
Histotripsy liver tumor trial successful, early clinical adoption recommended
The #HOPE4LIVER trials, testing the safety efficacy of histotripsy as a treatment for primary and metastatic liver tumors, met its goals for technical success and safety. An expert explains more about it in this article.
 stethoscope listening to phone with doctor projected out of it
Health Lab
Could your phone detect hepatic encephalopathy by listening to you read?
Research suggests that one day a phone app could be able to detect the development of hepatic encephalopathy in patients just by listening to them speak.
 bacteria blue yellow
Health Lab
New guideline for Helicobacter pylori includes change to primary treatment recommendation
The American Journal of Gastroenterology has published a new guideline on the treatment of Helicobacter pylori (H. pylori) Infection. 
 Photo portrait of Ryan Stidham, MD
Department News
Appointment of Ryan Stidham, M.D., M.S., as DCMB Associate Chair for Clinical and Translational Research and as Associate Director of the Center for Computational Medicine and Bioinformatics (CCMB)
Ryan Stidham, MD, MS, from the Department of Internal Medicine, is appointed as DCMB Associate Chair for Clinical and Translational Research and as Associate Director of the Center for Computational Medicine and Bioinformatics (CCMB)
 hands holding syringe white
Health Lab
How do GLP-1 weight loss drugs affect the liver?
Glucagon-like peptide-1, or GLP-1, receptor agonists, that aid in weight loss, are now being investigated for their ability to help other patients, including those with liver disease. However, a research letter discusses the first known case of hepatitis and jaundice in a patient taking these drugs.